All patients who received AGS-009 trended toward normal interferon-alpha (IFN-alpha) signatures after a single dose, while none of the patients receiving placebo showed a similar shift
Bristol-Myers Squibb Co., of New York, reported four-year results from the long-term extensions of the BENEFIT and BENEFIT-EXT trials evaluating Nulojix (belatacept), its selective T-cell co-stimulation blocker indicated for the prophylaxis of organ rejection in adult Epstein-Barr virus-seropositive patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil and corticosteroids
The median DFS was 14.1 months, and subgroup analyses showed patients receiving 300 million cells per dose had a 12-month DFS of 81 percent, while those receiving 100 million cells per dose had a 12-month DFS of 51 percent (p = 0.02
The company is investigating GAL-021 for improving breathing in patients receiving opioids, which are known to depress the respiratory system...Improvements in symptoms were maintained throughout the study in patients receiving aripiprazole, while patients on placebo worsened
In patients receiving telaprevir in combination with peginterferon alfa and ribavirin, SVR was achieved by 74 percent (291/395) of patients who received a dose reduction to less than or equal to 600 mg, and by 75 percent (38/51) who received a ribavirin dose reduction to 800 mg – 1,000 mg per day
The program consists of two 530-subject trials testing the drug in patients receiving highly emetogenic chemotherapy and one study enrolling about 1,350 patients receiving moderately emetogenic chemotherapy
Patients receiving the bavituximab regimen had median progression-free survival (PFS) of 5.8 months compared to 4.6 months in the group that had carboplatin/paclitaxel alone, a 26 percent improvement
Inc., of Whitehouse Station, N.J., said results from a 12-week post-treatment interim analysis of a Phase IIb study showed that a higher percentage of patients with genotype 1 hepatitis C virus (HCV) infection co-infected with HIV who were treated with protease inhibitor Victrelis (boceprevir) in combination with peginterferon alfa-2b and ribavirin had undetectable HCV RNA compared to patients receiving peginteferon alfa-2b and ribavirin alone
The trial is expected to involve 138 colorectal cancer patients receiving 5-fluorouracil (5-FU)-based chemotherapy who will receive the drug subcutaneously in parallel with 5-FU
Patients receiving the broad-spectrum lipid-antiviral conjugate showed a reduction in CMV viremia (CMV > 200 copies/mL) or disease compared to patients in the placebo arm (p = 0.001
Fifteen of 17 patients in the study survived to a year, and patients receiving target therapeutic doses demonstrated clinically significant improvements in six-minute walk distance and the Minnesota Living with Heart Failure Questionnaire
Data showed that, after 96 weeks of treatment, 48 percent of patients receiving ritonavir-boosted elvitegravir achieved and maintained HIV RNA levels less than 50 copies/mL, compared to 45 percent of patients in the raltegravir group, based on the Time to Loss of Virologic Response algorithm
The results showed that a single intravenous injection of Zybrestat, at varying doses, was well tolerated, with a decrease in polyp activity and reduction of subretinal flud and retinal edema in patients receiving Zybrestat compared to placebo
Inc., of Whitehouse Station, N.J., said results from a 24-week interim analysis of a 48-week Phase IIb study showed that 70.5 percent of patients (43/61) receiving its protease inhibitor Victrelis (boceprevir) in combination with peginterferon alfa and ribavirin had undetectable hepatitis C virus (HCV) compared to 34.4 percent (11/32) of patients receiving peginterferon alfa and ribavirin alone, for a treatment difference of 36.1 percent
All patients who received AGS-009 trended toward normal interferon-alpha (IFN-alpha) signatures after a single dose, while none of the patients receiving placebo showed a similar shift